A Phase I, open-label, single-dose, randomized, three-period crossover study to evaluate the relative bioavailability and food effect of GDC-6036 in healthy subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Divarasib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 14 Oct 2021 New trial record